If your company has developed a new drug or medical formulation, a pharmaceutical patent is the lock on your most valuable work. In Canada, filing correctly and on time can determine years of exclusive market access. Here is what businesses entering the Canadian pharmaceutical space need to understand before they begin.
What is a pharmaceutical patent under Canadian laws?
Under the federal Patent Act, a patent is a legal right that gives its holder the exclusive power to make, use, and sell an invention for a set period of time. In the pharmaceutical industry, this means an innovator company that discovers a new medicine can prevent competitors from copying it.
What qualifies for a patent in pharma
Patentable subject matter under the Patent Act must be an art, process, machine, manufacture, or composition of matter. In pharma, patents are commonly granted for:
- medicinal ingredient itself, which is the active compound in a drug
- specific formulation, i.e., how ingredients are mixed or layered together
- dosage form, e.g., a tablet, capsule, or injectable
- approved therapeutic use of a drug
After getting a pharmaceutical patent, it’s important to protect them against infringement. Learn more with this video:
Bookmark our Special Edition on Health Sciences Law for more news and updates, including the leading lawyers in this legal area.
What cannot be patented
Not everything in medicine qualifies for a patent. For instance, methods of medical treatment and surgery are not patentable in Canada. Dosage regimens, meaning the specific dose, frequency, and duration of treatment, sit in a legally contested space. This issue on patentability was examined by the Supreme Court of Canada in Pharmascience Inc. v. Janssen Inc., 2026 SCC 26.
One rule that no longer applies is the so-called “promise doctrine,” which once allowed courts to invalidate patents when a drug failed to meet every utility stated in its disclosure. The Supreme Court of Canada struck it down unanimously in AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36, ruling that “a scintilla of utility will do.” As such, one practical use is enough with regards to patentability.
How long does a drug patent last in Canada?
As with a pharmaceutical patent, the standard Canadian patent runs for 20 years from the date the application is filed. However, for pharmaceutical drugs, the effective period of market exclusivity is typically shorter.
This is because regulatory approval can take years, and by the time a drug receives its Notice of Compliance (NOC) from Health Canada, a large portion of the patent may already have run down.
Data protection
Separate from pharmaceutical patent law entirely, and arising under the Food and Drug Regulations of the Food and Drugs Act, data protection prevents generic drug manufacturers from filing for or receiving marketing approval for at least six to eight years after the original drug receives its NOC. This protection exists independently of any patent.
Certificate of Supplementary Protection (CSP)
Canada offers a Certificate of Supplementary Protection (CSP), which provides up to two additional years of exclusivity beyond patent expiry to compensate for regulatory delays.
There is a strict deadline; drug companies must apply within 120 days of their NOC being issued, and only one CSP can be granted per medicinal ingredient.
Canada’s two-year CSP cap is modest. As Daphne Lainson, chairwoman of Smart & Biggar LLP, observed in a 2021 Lexpert article on health sciences intellectual property, the extension “was only two years, unlike the five years given in most European countries.”
Patent Term Adjustment (PTA)
For patents issued after December 1, 2025, Canada is introducing a Patent Term Adjustment (PTA) system to compensate for delays caused by the patent office.
The application fee is $2,500, and only patents filed after December 1, 2020 are eligible. Given the narrow eligibility rules, few patents are expected to benefit materially for PTAs.
Are generic drugs in Canada protected by a patent?
Generic drugs cannot be patented, because they are not original inventions as they contain the same active medicinal ingredient as the brand-name drug. That said, they cannot simply enter the market at any time they choose.
Canada’s patent linkage system
The Patented Medicines (Notice of Compliance) Regulations connect drug marketing authorization to patent protection. When a generic company applies for its own marketing approval and references the innovator’s drug, it must address every patent listed on Health Canada’s Patent Register for that drug.
The generic company has two options:
- wait for the listed patents to expire before entering the market
- challenge the patents by filing a Notice of Allegation (NOA)
When an NOA is filed, the innovator is given 45 days to file an infringement action with the Federal Court. Filing that action blocks the generic’s approval for 24 months, or until the case is resolved.
Whether biosimilar drugs can be patented
Biosimilars face the same patent linkage regime. Unlike small-molecule generics, biosimilars are not exact copies. They are “highly similar” versions of biologic drugs made from living organisms.
Urszula Wojtyra, a principal at Smart & Biggar LLP in Toronto, described the scale of the difference in a July 2026 Lexpert article on biosimilars and Health Canada’s approval process: a small-molecule drug is comparable to a tennis ball in size, while a biologic drug can be likened to “the size of a hot-air balloon.”
What happens when a pharmaceutical patent expires?
When a pharmaceutical patent expires, the market opens. Generics enter, and competition typically drives prices down fast.
The “patent cliff”
When many patents expire around the same time, the pharmaceutical industry calls it a “patent cliff.” Lawyers in the pharmaceutical sector describe 2025 as the largest such cliff in 15 years, with an estimated US$240 billion in sales at risk for the top 25 biopharma companies by 2030.
Paul Armitage, head of the Vancouver technology industry group at Gowling WLG, noted in a July 2025 Lexpert article on licensing deals and the patent cliff that “licensing has always been one of the core business strategies” for biotech and pharma companies.
For Canadian patients, this means that:
- lower-cost generic alternatives become available once a patent falls away
- competition from generics and biosimilars can reduce costs for provincial drug plans
- biosimilar market entry may generate meaningful savings for publicly funded drug programs
Here’s a generic video that explains what happens when patents for name brand medicines expire:
Head over to our list of the best life sciences and health lawyers in Canada as ranked by Lexpert for the top-ranking lawyers and firms in this practice area.
Pharmaceutical patent: making the lock work for your business
That lock is only as strong as the patent strategy behind it. Filing a pharmaceutical patent in Canada involves strict timelines, cost considerations, and legal obligations that go well beyond the application itself. Whether your company is bringing its first drug to market or expanding an existing portfolio, engaging an experienced intellectual property or health sciences lawyer early in the process is the most direct way to protect what you have built.
Subscribe to the free Lexpert newsletter to read more articles on Canadian intellectual property and health sciences laws, such as pharmaceutical patents.